Pharma Pulse 10/14/24: Trial Site Engagement Models Poised for Disruption, Are PBMs Putting GLP-1 Drugs on Their Formularies? & more

Trial Site Engagement Models are Poised for Disruption

The role of the clinical research associate may be key in addressing challenges around the adoption of digital tools.

Are PBMs Putting GLP-1 Drugs on Their Formularies?

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.

MicroRNA Pioneers Win Nobel Prize in Medicine

Americans Victor Ambros and Gary Ruvkun discovered tiny molecules that affect gene regulation.

Humana Foundation Contributes Additional $500,000 to Support Disaster Recovery in Florida in the Aftermath of Hurricane Milton

The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM), is donating another $500,000 toward relief and healing efforts in the wake of the second Hurricane to hit Florida in two weeks. After consecutive disasters and concern for everyone in the path of these storms, the Humana Foundation will bring its total support to $1.5 million. Like the steps Humana took to aid members, communities and employees across the path of Hurricane Helene, it will do the same with Milton, by providing access to medical and emergency prescription information, and continuing access to a crisis hotline with free counseling.

Fitzsimons Innovation Community on LinkedIn

With over three decades in biotech, Max Colao, CEO of OncoVerity, is at the forefront of personalized cancer treatment. In this compelling interview with Pharmaceutical Executive, Colao discusses his journey from industry giants to leading the startup OncoVerity in revolutionizing oncology care through computational biology and machine learning.

“…we see the potential to double the overall lifespan for even the highest risk patients. And now we’re at the phase of proving ourselves in clinical trials, and we’re initiating a randomized control trial to test our design treatment approach versus the standard view.” – Max Colao

Along with Melissa Krebs, Ph.D., CEO, GelSana and Elyse Blazevich, President and CEO, CBSA, Colao was featured in Pharmaceutical Executive’s Profiles in Medicine series featuring leaders at the forefront of innovation.

#COLeadsLifeSciences #COLifeScienceFrontier #Innovation #FitzCommunity

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs